



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07C 233/49, 233/51, 231/02 A61K 31/195</p>	<p>A1</p>	<p>(11) International Publication Number: WO 90/08130</p> <p>(43) International Publication Date: 26 July 1990 (26.07.90)</p>
<p>(21) International Application Number: PCT/HU90/00004</p> <p>(22) International Filing Date: 16 January 1990 (16.01.90)</p> <p>(30) Priority data: 168/89 17 January 1989 (17.01.89) HU</p> <p>(71) Applicant (for all designated States except US): FOLLIGEN BUDAPEST LTD. [HU/HU]; Vörösmarty tér 2, H-1051 Budapest V (HU).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only) : LITERÁTI NAGY, Péter [HU/HU]; VII. u. 38, H-1172 Budapest (HU). KÉRI, György [HU/HU]; Modori u. 4, H-1021 Budapest (HU). BOROSS, Mária [HU/HU]; Pauler u. 4, H-1013 Budapest (HU). NÉMETH, Gábor [HU/HU]; Zsókvár u. 48, H-1157 Budapest (HU). SZILBEREKY, Jenő [HU/HU]; Szamos u. 7, H-1122 Budapest (HU). SZILÁGYI, Ildikó [HU/HU]; Tisza u. 68, H-2120 Dunakeszi (HU).</p>	<p>(74) Agent: DANUBIA; Bajcsy Zsilinszky ut 16, H-1368 Budapest (HU).</p> <p>(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.</p> <p style="text-align: center;">Published <i>With international search report.</i></p>	
<p>(54) Title: POLYUNSATURATED FATTY ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, METHOD FOR THE PREPARATION THEREOF, AND THEIR USE AS MEDICAMENT</p>		
$ \begin{array}{c} \text{O} \\ \parallel \\ \text{R}_1 - \text{C} - \text{X} - \text{CH} - \text{Y} \\ \\ \text{R}_2 \end{array} \quad (I) $		
<p>(57) Abstract</p> <p>The compounds of formula (I), wherein R₁ is a C₁₈₋₂₄ alkenyl containing at least two double bonds, X is O, NH or C₁₋₄ alkyl-N, Y is CONH₂, COOH or COOMe, wherein Me is metal, and R₂ is a side chain of a natural amino acid at α-position or a group of formulae (II): -(CH₂)_k - C₆H₅ - (OH)₂, (III): -(CH₂)_n - X - (CH₂)_m - X - Me or (IV): -(CH₂)_n - CH(NH₂) - COOH, wherein k is zero or an integer of 1, n is zero or an integer of 1 to 3, m is zero or an integer of 1 to 4, M is H or R₁-CO and X and R₁ are as defined above and their salts having tyrosine kinase inhibitor activity can be used as antitumor agents.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				


POLYUNSATURATED FATTY ACID DERIVATIVES, PHARMACEUTICAL
COMPOSITIONS CONTAINING THE SAME, METHOD FOR THE PREPARATION
THEREOF, AND THEIR USE AS MEDICAMENT

5

10

This invention relates to polyunsaturated fatty
acid derivatives and their salts with tyrosine kinase
inhibitor activity having the Formula (I)

15



20 wherein

 R_1

is an alkyl chain consisting of 18 to 24 carbon
atoms containing at least two unsaturated
double bonds;

X

is selected from oxygen, imino group, or

25

nitrogen substituted with alkyl group
consisting of 1 to 4 carbon atoms;


Y

is carboxyl, COOMe , or carboxamide group,
where

Me is metal;

30 R_2

is either a side-group to the alpha carbon atom
of any amino acid found in living organisms or
a group having the formula (II)




35

- 2 -

where

A is OH and $k = 0$ or 1
or a moiety having the formula (III)



where

X is as described above,

n is an integer from 0 to 3, inclusive,


10 m is an integer from 0 to 4, inclusive,

M is either hydrogen or $\text{R}_1\text{-CO}$ group

where

R_1 is as described above,

or a chain having the Formula (IV)



where

20 n is as defined above;

and to the method for preparation thereof.

Due to the immunostimulant and tyrosine kinase inhibitor activity, the compounds of the invention can be
25 applied for stopping and suppressing the pathological cell proliferation, consequently, for treating the malignant neoplastic diseases.

According to recent investigations, the formation of malignant tumors is clearly the result of the
30 abnormal activation of certain genes. The abnormal activation of these genes called proto-oncogenes and their transformation into oncogenes can be caused by several mechanisms independently of retroviruses. By definition, the term "oncogene" means that these genes permit the
35 formation and survival of malignant neoplastic cells

- 3 -

/Bradshaw, T.K.: Mutagenesis 1, 91 - 97 (1986)/.

In the present state of the art, the regulation of cell-division is carried out by a complex mechanism which consists of genomial information comprising
5 proto-oncogenes and the finely adjusted interaction between different factors inducing growth and differentiation and endocrine and paracrine regulators. The close connection between oncogenes and growth factors is also supported by the fact that the major part of oncogenes encodes proteins
10 which themselves are growth factors or growth factor receptors or which interact with the signal transduction mechanism induced by growth factors.

As each cell of an organism is part of a strictly regulated and systematic "cell society", it has
15 long been presumed that, normally, cells only begin to divide as an effect of an extrinsic signal i.e. growth factor. Recent investigations have also proved that, in the permanently dividing neoplastic cells, a growth factor transduction pathway is always active but, in certain
20 (pathological) cases, the exogene growth factor is replaced by an oncogene product [Winstein, B.; J. Cell. Biochem. 33, 213-224 (1987) and Paul, D.; Drug Res. 35, 772-779 (1985)].

Many of the consequent steps of the signal transduction mechanism are potential sites of oncogene
25 intervention.

Under the physiological conditions of regulated cell-division such as embriogenesis or regeneration of injured tissue, proto-oncogenes which take part in the regulation of cell-division are activated by growth factors.

30 In transformed cells containing activated oncogenes, the complex interaction signals and regulating mechanisms which normally appear in a tissue have stronger effects because the organism and the microenvironment tend to control the cells that "break loose".

- 4 -

In the present state of the art, all the tumors are monoclonal, that is, they originate from one single transformed cell. Tumor progression begins when these transformed cells become able to divide permanently in this special, "hostile" microenvironment, and the divisions result in viable variants. To be able to survive and divide in this competitive environment, neoplastic cells have to possess special division parameters and other favourable features such as resistance to immune effects. Thus, in the permanently dividing neoplastic cells, there is a signal transduction mechanism constantly "on" which induces cell division and with which inhibitory regulating signals of the environment are unable to interact [Nicolson, G.L.: Cancer Research 47, 1473 - 1487 (1987)].

In the present state of the art, the regulation of cell division is carried out by three main transduction mechanisms: the stimulation or inhibition of the tyrosine kinase pathway, the phospholipid metabolism protein kinase C pathway, and/or the CAMP protein kinase A pathway.

The significance of the tyrosine kinase transduction pathway is demonstrated by the fact that a major part of the oncogenes encodes tyrosine kinases and that growth factor receptors and receptors of autocrine growth factors secreted by neoplastic cells are mainly tyrosine kinase as well [Yarden et al.: Ann. Rev. Biochem. 57, 443 - 478 (1988)].

Accordingly, it can be established that the key to the therapy of malignant tumors will be given by the knowledge and selective inhibition of the specific signal transduction mechanism used by the oncogenes and growth factors.

The aim of the invention is, therefore, to synthesize a novel tyrosine kinase inhibitor that stops and suppresses the pathological cell proliferation as well

35

- 5 -

as prevents the development of malignant tumors by the inhibition of the activity of tyrosine kinase enzyme.

The invention is based on the discovery that
5 the said purpose can be realized completely by the application of polyunsaturated fatty acid derivatives of the invention, having the above Formula (I) wherein

R_1 is alkyl chain consisting of 18 to 24 carbon
atoms containing at least two unsaturated
10 double bonds;

X is selected from oxygen, imino group, or
nitrogen substituted with alkyl group
consisting of 1 to 4 carbon atoms;

Y is carboxyl, COOMe, or carboxamide group,
15 where

Me is metal;

R_2 is either a side-group to the alpha carbon atom
of any amino acid found in living organisms or
a group having the above Formula (II) where

20 A is hydroxyl and $k = 0$ or 1,
or a moiety having the above Formula (III)
where

X is as described above,

n is an integer from 0 to 3, inclusive,

25 m is an integer from 0 to 4, inclusive,

M is either hydrogen or R_1 -CO group
where

R_1 is as described above,
or a chain having the above Formula (IV)

30 where

n is as defined above.

- 6 -

Further, the invention is based on the discovery that compounds having the above Formula (I) when incorporated into the membranes of tumor cells are able to inhibit the signal transduction mechanisms activated by oncogenes and growth factors, consequently, the pathological cell proliferation is suppressed.

Compounds having the above Formula (I) have not been known in the literature up to now.

The known related compounds contain saturated fatty acid residues as R_1 in the above Formula (I). These compounds are excellent as detergents and skin food ingredients, mainly in cosmetics, due to their hydrating capability and skin softening activity. For example, such agents are described in the Japanese Patent No. 58.168,696 or in the Eur. Pat. No. 139,481. Hiroshi et al. [Chem. Pharm. Bull. 35, 2935 (1987)] prepared palmitoyl serine applying to the preparation of liposomes. Several papers, such as Paquet et al. [Can. J. Biochem. 58, 573 (1980)] or Berger et al. [Tenside 23, 156 (1986)] covered the applications of palmitoyl threonine and palmitoyl methionine in the food industry.

It is worth to note that a fatty acylated derivative of diethylene triamine is described as one of the components of a chemically multicomponent system in the Hungarian Patent No. 4348/83, used for regeneration of neoplastic cells and tissues.

This invention, therefore, relates to the methods of preparing polyunsaturated fatty acid derivatives and their salts having the above Formula (I), wherein the substituents are as described above, comprising acylation of a compound having the Formula (VI)



- 7 -

where

Q is selected from hydroxyl, amino or NHR amino-alkyl groups with an alkyl group of 1 to 4 carbon atoms as R,

5 Y and R₂ are as described above with a polyunsaturated fatty acid derivative having the Formula (V)



10

where

Z is hydroxyl or R₁-CO group with R₁ being either as described above or a halogen atom,

in the presence of an acid absorbent.

15

In accordance to this invention, the acylating agents having the above Formula (V) can be prepared preferably from γ -linolenic acid (GLA) (18:3n-6(Z)-6,9,-12-octadecatrienic acid) or from eicosapentaenic acid (EPA) 20 (20:5 ω -3(Z)-5,8,11,14,17) or from docosahexaenic acid (DHA) (22:6 ω -3(Z)-4,7,10,13,16,19) as starting materials.

The main source of GLA may be the oil obtained from plant seeds, such as evening primrose (*Oenothera biennis*, *Oenothera lamarkina*) or *Borago officinalis* e.g. 25 by the method of Brit. Pat. No. 2,183,635 or from the *Tetrahymena* ciliates by the method of French Pat. No. 2,574,089. As feedstocks for DHA and EPA or other typically C₁₈₋₂₄ ω -3 unsaturated fatty acids, oils from various salt-water and fresh-water fishes, mainly mackerels, 30 cods, herrings, sardines, calamaries, *Hypophthalmichthys* and from their livers, such as cod-liver oil or shark-liver oil may be used.

Polyunsaturated carboxylic acids are transformed into acyl halides having the above Formula (V) by 35 reacting them with inorganic acyl halides, such as SOCl₂,

- 8 -

POCl_3 , PCl_3 , PCl_5 by any method well-known in the art of organic chemistry.

In the acylating reaction, polyunsaturated fatty acyl halides can be replaced by the corresponding anhydrides obtained by reacting the sodium salt of the corresponding fatty acid with said inorganic acyl halide.

The desired acylating agent may also be prepared directly from the carboxylic acid by any other methods known in the art of organic chemistry.

In the method of this invention, the acylating agents having the above Formula (V), prepared as above, are reacted with compounds having the above Formula (VI) to obtain compounds having the above Formula (I) through N- or O-acylating.

In the acylating reaction, organic bases such as pyridine or triethylamine are used as catalysts and acid absorbents. The reaction may be conducted at 10 to 120 °C with or without solvent. In some cases, the said organic bases may be used as solvents.

Since polyunsaturated fatty acid derivatives are immiscible with water, the acylating reaction may be conducted in the aqueous alkalic medium by the Schotten-Baumann's method.

The biochemical and biological features of compounds having the above Formula (I) are as follows:

The effect of compounds having the above Formula (I) on the enzymatic activity of tyrosine kinase was measured by the method of Schwarup et al. [J. Biol. Chem. 258, 10341 - 10347 (1984)] using treated and untreated rat spleen homogenisates.

For this test, 100 cm³ of stock solution containing 50 millimoles of TRIS-Cl (at pH 7.8), 50 millimoles of magnesium chloride, 10 micromoles of

- 9 -

sodium vanadate, 0.1 percent of Nonidet P-40 (from Fluka A.G., Buchs, Switzerland), and 1 millimole of Angiotensin II was mixed with 60 mm³ of rat spleen homogenisate. The reaction was started by the addition of 0.5 nanomole of (³²P)ATP. The reaction mixture was incubated at 30 °C for 10 min then the reaction was stopped by the addition of 150 mm³ of 1 percent solution of trichloroacetic acid. 10 mm³ of bovine serum albumine (at a concentration of 20 mg/cm³) was added to the mixture and the precipitated protein was removed by centrifuging (3200 g for 25 min). 50 mm³ aliquot of the supernatant liquid was dropped onto a Whatman P-81 phosphocellulose paper. The paper squares were washed six times with 0.5 percent phosphoric acid and once with acetone then dried. Their radioactivities were measured in 5 cm³ of scintillation liquid. The results are collected in the following Table:

Test substrate: rat spleen homogenisate

Activities of spleens: 0.7135 pmole³²P/mg protein/min
 1.0119 pmole³²P/mg protein/min
 1.258 pmole³²P/mg protein/min

Serial number	Materials tested		Activity pmole ³² P/mg/min	Tyrosine kinase activity (%)	Matter content (mg)
	Number of example	Amount (mm ³)			
1	2	3	4	5	6
1	24 C	20	0.7932	100	
	24	20	a) 0.9527	120	1.8
			b) 1.7148/1 mg		
	24 C	50	0.900	100	
35	24	50	0.1585	17.6	4.5

- 10 -

	1	2	3	4	5	6
5	2	17 C	20	0.8906	100	
		17	20	0.0942	10.5	1
		17 C	50	0.885	100	
		17	50	0	0	2.5
10	3	C = compound of Example 17.				
		16	20	0.043	4.8	1
		16	50	0	0	2.5
15	4	C = DMSO				
		18	20	0.6917	62.18	1
		18	20	0.3175	26.74	2.5
20	5	C = DMSO				
		20	20	0.4088	36.98	1
		20	20	0	0	2.5
25	6	14 C	20	1.1004	100	
		14	20	0	0	1
		14 C	50	0.701	100	
		14	50	0	0	2.5
	7	15	20	0.08512	7.735	1
		15	50	0	0	2.5

C = control

30

35

- 11 -

The immunostimulating activity of compounds having the above Formula (I) was measured by the activation lymphocyte cells by virtue of polyclonal mytogenes as follows:

5

Two hundred thousand cells of a lymphocyte population obtained on Ficoll Uromiro gradient [Å. Böyum: Scand. J. Clin. Lab. Invest. 21, 97 (1986)] were pipetted into the reservoirs of flat-bottom microplates to form 7
10 parallel cultures. 25 $\mu\text{g}/\text{cm}^3$ of Concanavalin A (Con A, Pharmacia, Sweden) was added to each sample. The control solution was 25 $\mu\text{g}/\text{cm}^3$ of Con A without any other ingredients. The plates were grown in an environment containing 5 percent of CO_2 at 37 °C for 72 hours.
15 8 hours before the end of growth, each sample was supplemented by 0.4 μCi of ^3H -thymidine. Passing of 72 hours, the cultures were filtered on a glass filter each. The filters were placed into scintillation
cuvettes and 5 cm^3 of Liquifluor-containing toluene
20 solution was added. The samples were measured in a Nuclear Chicago Isocap 300 beta counter and activities were read in count/min (cpm).

25

30

35

- 12 -

		Spontaneous	5 μ g/ml Con A	25 μ g/ml Con A
	Basic level:	161 \pm -19	16387 \pm -3017	28419 \pm -3967
	Product of Example 14			
5	0.1 μ g/ml:	179 \pm -36	12287 \pm -2480	30749 \pm -4096
	p:	n.s.	0.01	n.s.
	1.0 μ g/ml:	228 \pm -48	13513 \pm -2584	30728 \pm -3691
	p:	n.s.	0.01	n.s.
	10 μ g/ml:	183 \pm -25	10078 \pm -1951	25303 \pm -3500
10	p:	n.s.	0.01	0.05
	Product of Example 16			
	0.1 μ g/ml:	139 \pm -21	12932 \pm -2436	31470 \pm -3960
15	p:	n.s.	0.001	0.05
	1.0 μ g/ml:	219 \pm -38	133010 \pm -2560	32735 \pm -4293
	p:	n.s.	0.02	0.02
	10 μ g/ml:	150 \pm -25	10608 \pm -2061	25551 \pm -3791
20	p:	n.s.	0.01	n.s.
	Product of Example 15			
	0.1 μ g/ml:	151 \pm -18	11759 \pm -1735	27780 \pm -3245
	p:	n.s.	n.s.	n.s.
25	1.0 μ g/ml:	172 \pm -26	12082 \pm -2065	27106 \pm -3296
	p:	n.s.	n.s.	n.s.
	10 μ g/ml:	158 \pm -19	8336 \pm -1452	20316 \pm -2827
	p:	n.s.	0.05	0.01
30	c.p.m. average \pm SEM			
	n = 12			
	n.s. = not significant			

- 13 -

The active ingredients having the above Formula (I) may be processed into capsules, tablets or other known pharmaceutical formulations along with pharmaceutically acceptable carriers and/or additives in the usual pharmaceutical ways.

The principal advantages of the compounds and pharmaceutical preparations of this invention are as follows:

1. Through the inhibition of the enzymatic activity of tyrosine kinase, a suppression of the signal transduction mechanisms activated by growth factors and/or oncogenes is provided leading to an inhibition of pathological cell proliferation processes.
2. The antioxidant and immunostimulating activity of the polyunsaturated fatty acid component gives a possibility to the complex tumor therapy.
3. Suppression of the pathological cell proliferation through the inhibition of tyrosine kinase is a much more gentle intervention than the conventional chemotherapy, such as a cytostatic treatment.

The following examples are presented to illustrate the method of this invention but are not intended to limit its scope.

- 14 -

Example 1Preparation of (Z)-5,8,11,14,17-eicosapenta-
enoyl chloride(EPA-C1)

- 5 0,303 g (0.001 mole) of EPA was dissolved
in 3 cm³ of cyclohexane. The solution was placed into a
round-bottom flask equipped with a loading funnel and
0.092 g of PCl₃, dissolved in 1 cm³ of cyclohexane was
introduced under a continuous N₂ stream at 50 °C.
10 The mixture was stirred at room temperature
for an hour. The reaction mixture was then clarified by
activated charcoal and filtered. After evaporation, a yield
of about 95 percent was obtained. Characteristic infrared
absorption bands of the product:
15 1780 (CO), 1645 (C = C), 1460, 1440, 1370, 1340,
1290, 1240, 1170, 1095, 1015 cm⁻¹.

Example 2Preparation of (Z)-4,7,10,13,16,19-docosahexa-
enoyl chloride(DHA C1)

- 20 The same procedure as in Example 1 but EPA
was replaced by 0,329 g (0.001 mole) of DHA.
Yield was about 94 percent.
25 Infrared bands: 1780 (CO) cm⁻¹.

Example 3Preparation of (Z)-6,9,12-octadecatrienoyl
chloride(GLA-C1)

- 30 The same procedure as in Example 1 but EPA
was replaced by 0.278 g (0.001 mole) of GLA.
Yield was about 88 percent.
Infrared bands: 1780 (CO), 1650 (C = C) cm⁻¹.

35

- 15 -

Example 4

Preparation of a mixture of polyunsaturated fatty acyl chlorides containing 30.5 percent of EPA-Cl and 49.1 percent of DHA-Cl

5 165 g (0.5 mole) of a mixture of polyunsaturated fatty acids containing 30.4 percent of EPA and 49.0 percent of DHA was dissolved in 500 cm³ of cyclohexane. The solution was placed into a three-necked round-bottom flask equipped with a reflux condenser and a loading funnel
10 and was heated to 60 °C with continuous stirring.

A tube filled with CaCl₂ was connected to the top of the condenser and a slow N₂ stream was applied. From the loading funnel, 45.8 g (0.33 mole) of PCl₃ was added dropwise to the solution with continuous stirring
15 during 1 to 1.5 hour period. After the introduction, the mixture was stirred for another 1 to 1.5 hours at 60 °C. Deposited H₃PO₃ was removed from the cyclohexane solution by decantation. After clarification by activated charcoal, the solution was filtered then evaporated in vacuo.
20 166 g of acyl chloride was obtained at a yield of about 95 percent. Composition of the feedstock and the product was checked by HPLC.

25

Example 5

Preparation of N-eicosapentaenoyl (4-hydroxy-phenyl)-glycine

1.67 g (0.01 mole) of D,L-4-hydroxyphenyl glycine then 15 cm³ of freshly distilled pyridine were
30 placed into a round-bottom flask equipped with a reflux condenser and a loading funnel.

The mixture was heated to 60 to 65 °C and at this temperature, 3.85 g (0.012 mole) of EPA-Cl was introduced dropwise with continuous stirring during an hour.

35

- 16 -

As the introduction had been finished, the reaction mixture was allowed to cool down and stirring was continued for 2 hours.

Pyridine was evaporated in vacuo, the residue
5 was malaxated with water then extracted three times with ethyl acetate. The extract was washed twice with 0.5 percent hydrochloric acid then once with water, dried on dehydrated Na_2SO_4 and, finally, the solvent was evaporated. Yield was about 78 percent.

10 Infrared bands: 1695 ($\text{C}=\text{O}$), 1620 ($\text{C}=\text{O}$ amide), 3200 ($-\text{NH}$, $-\text{OH}$) cm^{-1} .

Characteristic NMR signals in CDCl_3 to the amino acid moiety:
8.8 (bs) 3H, 6.9 (d) and 6.7 (d) 4H;
to the fatty acid moiety:

15 5.35 (m), 2.85 (s), 2.50 - 1.40 (m), 0.98 (t) ppm.

Example 6

Preparation of N-eicosapentaenoyl L-tyrosine

20 The same procedure as in Example 5 but D,L-4-hydroxyphenyl glycine was replaced by 1.81 g (0.01 mole) of L-tyrosine. Yield was about 62.5 percent.

Infrared bands: 1690 (CO), 1620 (CO amide), 3200 ($-\text{NH}$, $-\text{OH}$) cm^{-1} .

25 NMR signals in CDCl_3 : 8.5 (bs) 3H, 6.7 (d) and 6.9 (d) 4H, 4.85 (q) 1H, 3.1 (d) 2H ppm while the signals to the fatty acid moiety were identical to those in Example 5.

30

35

- 17 -

Example 7Preparation of N-eicosapentaenoylL-(3,4-dihydroxyphenyl- α -methyl)-alanine

The same procedure as in Example 5 but

5 D,L-4-hydroxyphenyl glycine was replaced by 2.11 g (0.01 mole) of 3,4-dihydroxyphenyl- α -methylalanine.

Yield was about 63.5 percent.

Infrared bands: 1695 (CO), 1620 (CO amide),
3150 (-NH, -OH) cm^{-1} .

10 NMR signals in CDCl_3 : 8.8 (bs) 4H, 6.50 (d) and
6.62 (s) and 6.75 (d) 3H, 5.0 (q) 1H, 3.15 (dd)
2H ppm.

The signals to the fatty acid moiety were identical to those
in Example 5.

15

Example 8Preparation of N-docosahexaenoyl (4-hydroxy-
phenyl)-glycine

20 The same procedure as in Example 5 but EPA-Cl
was replaced by 4.16 g (0.012 mole) of DHA-Cl prepared
as in Example 2. Yield was about 72.5 percent.

IR and NMR spectra were identical to those in Example 5.

25

Example 9Preparation of N-docosahexaenoyl L-tyrosine

The same procedure as in Example 5 but 1.81 g

(0.012 mole) L-tyrosine was used as the amino acid

30 solvent and EPA-Cl was replaced by 4.16 g (0.012 mole)
DHA-Cl. Yield was about 77 percent.

IR and NMR spectra were identical to those in Example 6.

35

- 18 -

Example 10Preparation of N-docosahexaenoyl L-(3,4-dihydroxyphenyl- α -methyl)-alanine

5 The same procedure as in Example 5 but 2.11 g (0.01 mole) of L-methyl dopa was used as amino acid and EPA-Cl was replaced by 4.16 g (0.012 mole) of DHA-Cl. Yield was about 65.6 percent.

IR and NMR spectra were identical to those in Example 7.

10

Example 11Preparation of N-octadecatrienoyl (4-hydroxy-phenyl)-glycine

15 The same procedure as in Example 5 but EPA-Cl was replaced by 3.56 g (0.012 mole) of GLA-Cl prepared as in Example 3. Yield was about 73.8 percent.

IR and NMR spectra were identical to those in Example 5.

20

Example 12Preparation of N-octadecatrienoyl L-tyrosine

The same procedure as in Example 5 but 1.81 g (0.01 mole) of L-tyrosine was used as amino acid and EPA-Cl was replaced by 3.56 g (0.012 mole) of GLA-Cl.

25 Yield was about 64.7 percent.

IR and NMR spectra were identical to those in Example 6.

Example 13

30

Preparation of N-octadecatrienoyl L-(3,4-dihydroxy-phenyl- α -methyl)-alanine

The same procedure as in Example 5 but 2.11 g (0.01 mole) of α -methyl dopa was used as amino acid and EPA-Cl was replaced by GLA-Cl. Yield was about 61.3 per-

35 cent.

- 19 -

IR and NMR spectra were identical to those in Example 7.

Example 14

5 Acylating of (4-hydroxyphenyl)-glycine

The same procedure as in Example 5 but EPA-Cl was replaced by 4.2 g (0.012 mole) of the mixture of polyunsaturated fatty acyl chlorides as prepared in Example 4. Yield of the mixed product was about 88 percent, containing N-eicosapentaenoyl (4-hydroxyphenyl)-glycine and N-dicosahexaenoyl (4-hydroxyphenyl)-glycine as the main components.

Infrared bands: 1695 (CO), 1620 (CO amide), 3200 (-NH, -OH) cm^{-1} .

15 NMR signals in CDCl_3 : 8.5 (bs) 3H, 6.9 (d) and 6.7 (d) 4H, 5.35 (m) 11H, 2.85 (s) 9H, 2.5 - 1.5 (m) 8H, 0.98 (t) 3H characteristic to the fatty acid.

20

Example 15

Acylating of L-tyrosine with the mixture of Example 4

The same procedure as in Example 5 but 1.81 g (0.01 mole) of L-tyrosine was used as amino acid and EPA-Cl was replaced by 4.2 g of the mixture of polyunsaturated fatty acyl chlorides as prepared in Example 4. Yield of the mixed product was about 66.2 percent, containing N-eicosapentaenoyl tyrosine and N-docosa-hexaenoyl tyrosine as the main components.

Infrared bands: 1680, 1620, 3150 cm^{-1} .

NMR signals in CDCl_3 : 8.50 (bs) 3H, 6.90 (d) 4H, 6.70 (d), 4.85 (q) 1H, 3.10 (d) 2H ppm.

Signals characteristic to the fatty acid moiety were

35

- 20 -

identical to those in Example 14.

Example 16

5 Acylating of L-serine with the mixture of Example 4

The same procedure as in Example 5 but 0.01 mole of L-serine was used as amino acid and 0.012 mole of the mixture of polyunsaturated fatty acyl chlorides prepared
10 in Example 4 was applied as fatty acyl chloride. Yield of the mixed product was about 56.7 percent, containing N-eicosapentaenoyl L-serine and N-docosa-hexaenoyl L-serine as the main components. Infrared bands: 1890, 1620, 3150 cm^{-1} .
15 NMR signals in CDCl_3 : 9.40, 8.40, 7.95 (s) 1H each, 4.50 (m) 1H, 3.90 (dd) 2H. Signals characteristic to the fatty acid moiety were identical to those in Example 5.

20

Example 17

Acylating of L-threonine

The same procedure as in Example 5 but 0.01 mole of L-threonine was used as amino acid and 0.012 mole
25 of the mixture of polyunsaturated fatty acyl chlorides prepared in Example 4 was applied as fatty acyl chloride. Yield of the mixed product was about 62.5 percent, containing N-eicosapentaenoyl L-threonine and N-docosa-hexaenoyl L-threonine as the main components.
30 Infrared bands: 1690 (CO), 1620 (CO amide), 3150 (-NH, -OH) cm^{-1} . NMR signals in CDCl_3 : 7.35 (bs) 3H, 4.50 (d) 1H, 4.40 (m) 1H, 1.20 (d) 3H ppm, characteristic to the amino acid residue. Signals to the fatty acid moiety were.

35

- 21 -

identical to those in Example 5.

Example 18

5 Acylating of L-ornithine.HCl

The same procedure as in Example 5 but 1.63 g (0.01 mole) of L-ornithine hydrochloride was used as amino acid and 0.012 mole of the mixture of polyunsaturated fatty acyl chlorides prepared in Example 4 was applied as
10 fatty acyl chloride. Yield of the mixed product was about 45.5 percent, containing N²-eicosapentaenoyl L-ornithine.HCl and N²-docosahexaenoyl L-ornithine.HCl as the main components.

15 Infrared bands: 1690 (CO), 3100 (-NH), 1630 (C = O amide) cm⁻¹.

NMR signals characteristic to the amino acid moiety in CDCl₃: 8.30 - 7.30 (bs) 5H, 4.50 (m) 1H, 3.25 (m) 2H, 2.35 (m) 2H, 1.60 (m) 2H ppm.

20

Example 19

Acylating of L-lysine.HCl

The same procedure as in Example 5 but 1.83 g (0.01 mole) of L-lysine hydrochloride was used as amino
25 acid and 0.012 mole of the mixture of polyunsaturated fatty acyl chlorides prepared in Example 4 was applied as fatty acyl chloride. Yield of the mixed product was about 43.2 percent, containing N²-eicosapentaenoyl L-lysine.HCl and N²-docosahexaenoyl L-lysine.HCl as the main components.

30 Infrared bands: 1690 (CO), 1630 (CO amide), 3150 (-NH) cm⁻¹.

NMR signals in CDCl₃: 8.30 - 7.30 (bs) 5H, 4.50 (m) 1H, 3.25 (m) 2H, 2.30 (m) 2H, 1.50 (m) 4H ppm.

35

- 22 -

Example 20Acylating of L-arginine.HCl

The same procedure as in Example 5 but 2.11 g (0.01 mole) of L-arginine hydrochloride was used as amino acid and the mixture of polyunsaturated fatty acyl chlorides prepared in Example 4 was applied as fatty acyl chloride. In the extraction step, ethyl acetate was replaced by n-butanol. Yield of the mixed product was about 57.1 percent, containing N²-eicosapentaenoyl L-arginine.HCl and N²-docosahexaenoyl L-arginine.HCl as the main components. Infrared bands: 1695 (CO), 1625 (CO amide), 3200 (-NH, -OH) cm⁻¹. NMR signals in CDCl₃: 8.50 (bs) and 7.60 (bs) and 6.80 (bs) 7H, 4.40 (bs) 1H, 3.30 (bs) 2H, 1.50 (m) 4H ppm. Signals characteristic to the fatty acid moiety were identical to those in Example 5.

20

Example 21Acylating of α -methyl dopa

The same procedure as in Example 5 but 2.11 g (0.01 mole) of (3,4-dihydroxyphenyl- α -methyl)-alanine was used as amino acid and the mixture of polyunsaturated fatty acyl chlorides prepared in Example 4 was applied as fatty acyl chloride. Yield of the mixed product was about 67.8 percent, containing N-eicosapentaenoyl α -methyl-dopa and N-docosahexaenoyl α -methyl-dopa as the main components. NMR signals characteristic to the amino acid moiety in CDCl₃: 8.80 (bs) 4H, 6.75 (d) and 6.62 (s) and 6.50 (d) 3H, 5.00 (q) 1H, 3.15 (dd) 2H. Signals characteristic to the fatty acid moiety were identical to those in Example 5.

35

- 23 -

Example 22Acylating of diethylene triamine

2.12 g (0.04 mole) of diethylene triamine, 8.88 g (0.088 mole) of triethylamine and 150 cm³ of anhydrous toluene were placed into a four-necked round-bottom flask. The mixture was heated to 85 to 90 °C then 29.08 g (0.08 mole) of the mixture of fatty acyl chlorides prepared as in Example 4 was added dropwise with continuous stirring. The mixture was continued to stir at this temperature for 4 hours then 2.9 g (0.008 mole) of the said fatty acyl chloride mixture was additionally dropped in and stirring was continued for 2 hours more.

Precipitated triethylamine hydrochloride was filtered at room temperature and filtrate was evaporated under N₂ atmosphere at 4000 N/m². The residue was washed with petroleum ether. Yield of the mixed product was about 62.4 per cent, containing N,N'-[bis(aminoethylene)-imino]-bis-docosahexaenoate and N,N'-[bis(aminoethylene)-imino]-bis-eicosapentaenoate as the main components. Infrared bands: 1645 (CO amide), 3250 (-NH) cm⁻¹. NMR signals in CDCl₃: 3.55 (m) 8H (N-CH₂-) ppm and twice of the signals characteristic to the fatty acid moiety as in Example 5.

25

Example 23Acylation of diethanolamine

2.83 g (0.02 mole) of diethanolamine hydrochloride then 15 cm³ of dioxane were placed into a round-bottom flask equipped with a reflux condenser and a loading funnel. The mixture was heated to 55 to 60 °C and 13.6 g (0.04 mole) of the mixture of fatty acyl chlorides prepared as in Example 4 was added at that temperature during 1 hour period.

35

- 24 -

- The reaction mixture was continued to stir for 2 hours followed by evaporation at a pressure of 5400 N/m^2 . The residue was washed with petroleum ether. Yield of the mixed product was about 92.6 percent, containing
- 5 O,O'-(diethanolamine)-bis-docosahexaenoate.HCl and O,O-(diethanolamine)-bis-docosahexaenoate.HCl as the main components. Infrared bands: 1720 (CO ester) , $3100 \text{ (-NH) cm}^{-1}$. NMR signals in CDCl_3 : 10.0 (s) 1H , $4.0 - 4.4 \text{ (m) 4H}$, $3.3 - 3.7 \text{ (m) 4H ppm}$.
- 10 Signals characteristic to the fatty acid moiety were identical to those in Example 5.

Example 24

15 Acylation of L-lysine

- 5.61 g (0.034 mole) of L-lysine monohydrate was dissolved in 150 cm^3 of distilled water in a round-bottom flask equipped with magnetic stirrer. The solution was heated to 80°C and, with continuous
- 20 stirring, $\text{Cu(OH)}_2 \cdot \text{CuCO}_3 \cdot x\text{H}_2\text{O}$ was added in small portions until it appeared to be dissolved. The possible excess of $\text{Cu(OH)}_2 \cdot \text{CuCO}_3 \cdot x\text{H}_2\text{O}$, remained after stirring for 15 minutes, was filtered out. The solution was cooled to room
- 25 temperature with continued stirring and 1.8 g (0.017 mole) of Na_2CO_3 then 12.2 g (0.034 mole) of the mixture of fatty acyl chlorides prepared as in Example 4 were added dropwise. After 1-hour stirring, the acylated copper complex precipitate was filtered then washed once with
- 30 methanol and several times with water until a colourless wash liquor had been obtained. In a round-bottom flask, 200 cm^3 of methanol was added to the copper complex and the complex was decomposed by bubbling gaseous H_2S through the mixture.

- 25 -

The reaction mixture was filtered and the solvent was evaporated under N_2 atmosphere at a pressure of 5400 N/m^2 not above 50°C . The residue was washed with petroleum ether, malaxated with acetone, filtered and dried under N_2 atmosphere in both cases. Yield of the mixed product was 17.24 percent.

M.p.: 116°C (with decomposition).

N^6 -eicosapentaenoyl L-lysine and N^6 -docosa-hexaenoyl L-lysine were the main components of the product.

		Calculated	Found
	C	73.12	72.98
15	H	9.71	9.92
	N	6.33	6.18

Example 25

20 Preparation of N^5 -docosahexaenoyl L-ornithine

The same procedure as in Example 24 but L-lysine was replaced by 0.034 mole of L-ornithine and the mixture of acyl chlorides was replaced by DHA-Cl prepared as in Example 2. Yield was about 15.6 percent.

25

		Calculated	Found
	C	73.30	72.84
	H	9.50	9.61
30	N	6.33	6.51

35

- 26 -

Example 26Preparation of N⁶-docosahexaenoyl L-lysine

The same procedure as in Example 24 but the mixture of acyl chlorides was replaced by DHA-Cl prepared as in Example 2. Yield was 20.42 percent.

		Calculated	Found
10	C	73.68	74.10
	H	9.65	9.72
	N	6.14	6.21

15

20

25


30

35

- 27 -

What is claimed is:

1. A compound of the Formula (I)




wherein

R_1 is an alkyl chain consisting of 18 to 24 carbon atoms containing at least two unsaturated double bonds;

X is oxygen, imino group, or a nitrogen substituted with an alkyl group consisting of 1 to 4 carbon atoms;


Y is carboxyl, COOMe where Me is metal or carboxamide group;

R_2 is either a side-group to the alpha carbon atom of any amino acid found in the living organisms or a group having the Formula (II)



where

A is hydroxyl and $k = 0$ or 1 , or a moiety having the Formula (III),



where

X is as described above,

- 28 -


n . is an integer from 0 to 3, inclusive,

m . is an integer from 0 to 4, inclusive,

M is either hydrogen or R_1 -CO group

where


5 R_1 is as described above,
or a chain having the Formula (IV),



where

n is as defined above,

15 2. A pharmaceutical composition having
immunostimulating activity mainly for treating neoplastic
cells and tissues, comprising one or more compounds of
Formula (I)



25 where


X, Y, R_1 and R_2 are as defined in Claim 1,
and/or a salt thereof together with a pharmaceutically
acceptable carrier and/or other excipient.

30

35

- 29 -

3. A method for the preparation of poly-unsaturated fatty acid derivatives and their salts having the Formula (I)




where

10 R_1 is an alkyl chain consisting of 18 to 24 carbon atoms containing at least two unsaturated double bonds;

X is oxygen, imino group, or a nitrogen substituted with an alkyl group consisting of 1 to 4 carbon atoms;


15 Y is carboxyl, COOMe where Me is metal or carboxamide group;

R_2 is either a side-group to the alpha carbon atom of any amino acid found in the living organisms or a group having the Formula (II)



where

25 A is hydroxyl and $k = 0$ or 1 , or a moiety having the Formula (III)



X is as described above,

n is an integer from 0 to 3, inclusive,

30 m is an integer from 0 to 4, inclusive,


M is either hydrogen or $\text{R}_1\text{-CO}$ group

where

R_1 is as described above, or a chain having the Formula (IV),

35

- 30 -



5

where

n is as defined above

comprising acylation of a compound having the Formula (VI)



wherein

15 Q is selected from hydroxyl, amino, and NHR
aminoalkyl groups

where

R is an alkyl group consisting of 1 to 4
carbon atoms,

Y and R₂ are as described above

20 with a polyunsaturated fatty acid derivative having the
Formula (V)



25 wherein

Z is hydroxyl or R₁-CO group with R₁ being
either as described above or a halogen atom,
in the presence of an acid absorbent.

30


35

- 31 -

4. A method of Claim 3 comprising applying pyridine as the reaction medium and as acid absorbent.

5. A method of Claims 3 and 4 comprising conducting the acylation reaction between 0 and 120 °C.

6. A method for the preparation of a pharmaceutical composition having immunostimulating activity mainly for treating neoplastic cells and tissues comprising bringing one or more compounds having the Formula (I)




wherein

20 X, Y, R₁ and R₂ are as defined in Claim 1, and/or a salt thereof into association with a pharmaceutically acceptable carrier and/or other excipient.

25

7. Use of a compound of Formula (I)






wherein

X, Y, R₁ and R₂ are as defined in Claim 1, having immunostimulating activity for treating neoplastic cells and tissues.

35

INTERNATIONAL SEARCH REPORT

International Application No PCT/HU 90/00004

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁴ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : C 07 C 233/49, C 07 C 233/51, C 07 C 231/02, A 61 K 31/195.																				
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">Int.Cl.⁵:</td> <td style="padding: 5px;">C 07 C 233/49, C 07 C 233/51, C 07 C 231/02, C 07 C 69/587.</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁶</div>			Classification System	Classification Symbols	Int.Cl. ⁵ :	C 07 C 233/49, C 07 C 233/51, C 07 C 231/02, C 07 C 69/587.														
Classification System	Classification Symbols																			
Int.Cl. ⁵ :	C 07 C 233/49, C 07 C 233/51, C 07 C 231/02, C 07 C 69/587.																			
III. DOCUMENTS CONSIDERED TO BE RELEVANT¹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category ²</th> <th style="width: 60%; border-bottom: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%; border-bottom: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">JP, A, 63-230 663 (NIPPON OILS AND FATS CO.) 27 September 1988 (27.09.88), see examples 1-3.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">(1-6)</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">Chemical Abstracts, Vol. 111, No. 14 issued 1989, October 2 (Columbus, Ohio, USA), H. Hibino et al. "Infusion solutions containing N-highly unsaturated acyl-α-amino acid derivatives", see page 364, column 1, the abstract no. 120 892z, JP, A, 63-230 630 (NIPPON OILS AND FATS CO.).</td> <td style="text-align: center; vertical-align: top; padding: 5px;">(1,2,6)</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">JP, A, 53-52 631 (OGAWA KOUICHI) 13 March 1978 (13.05.78), see example 5.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">(1)</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">FR, A, 1 603 799 (J. MORELLE et al.) 02 July 1971 (02.07.71), see page 2, line 16.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">(1)</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">US, A, 3 624 114 (J.V. MORELLE) 30 November 1971 (30.11.71), see examples 5,10.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">(1,3,5)</td> </tr> </table>			Category ²	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	JP, A, 63-230 663 (NIPPON OILS AND FATS CO.) 27 September 1988 (27.09.88), see examples 1-3.	(1-6)	X	Chemical Abstracts, Vol. 111, No. 14 issued 1989, October 2 (Columbus, Ohio, USA), H. Hibino et al. "Infusion solutions containing N-highly unsaturated acyl- α -amino acid derivatives", see page 364, column 1, the abstract no. 120 892z, JP, A, 63-230 630 (NIPPON OILS AND FATS CO.).	(1,2,6)	A	JP, A, 53-52 631 (OGAWA KOUICHI) 13 March 1978 (13.05.78), see example 5.	(1)	A	FR, A, 1 603 799 (J. MORELLE et al.) 02 July 1971 (02.07.71), see page 2, line 16.	(1)	A	US, A, 3 624 114 (J.V. MORELLE) 30 November 1971 (30.11.71), see examples 5,10.	(1,3,5)
Category ²	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																		
X	JP, A, 63-230 663 (NIPPON OILS AND FATS CO.) 27 September 1988 (27.09.88), see examples 1-3.	(1-6)																		
X	Chemical Abstracts, Vol. 111, No. 14 issued 1989, October 2 (Columbus, Ohio, USA), H. Hibino et al. "Infusion solutions containing N-highly unsaturated acyl- α -amino acid derivatives", see page 364, column 1, the abstract no. 120 892z, JP, A, 63-230 630 (NIPPON OILS AND FATS CO.).	(1,2,6)																		
A	JP, A, 53-52 631 (OGAWA KOUICHI) 13 March 1978 (13.05.78), see example 5.	(1)																		
A	FR, A, 1 603 799 (J. MORELLE et al.) 02 July 1971 (02.07.71), see page 2, line 16.	(1)																		
A	US, A, 3 624 114 (J.V. MORELLE) 30 November 1971 (30.11.71), see examples 5,10.	(1,3,5)																		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>																				
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">01 March 1990 (01.03.90)</td> <td style="border-bottom: 1px solid black; padding: 5px;">20 March 1990 (20.03.90)</td> </tr> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">International Searching Authority</td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Signature of Authorized Officer</td> </tr> <tr> <td style="padding: 5px;">AUSTRIAN PATENT OFFICE</td> <td style="padding: 5px; text-align: center;"></td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	01 March 1990 (01.03.90)	20 March 1990 (20.03.90)	International Searching Authority	Signature of Authorized Officer	AUSTRIAN PATENT OFFICE											
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																			
01 March 1990 (01.03.90)	20 March 1990 (20.03.90)																			
International Searching Authority	Signature of Authorized Officer																			
AUSTRIAN PATENT OFFICE																				

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	Chemical Abstracts, Vol. 106, No. 11, issued 1987, March 16 (Columbus, Ohio, USA) A. Vamvakides "Effect of GABA linoleamide and glycine linoleamide on pentamethylenetetrazole-induced convulsions", see page 52, column 2, the abstract no. 78 590u, J. Pharmacol. 1986, 17(3), 323-7.	(1)
A	Chemical Abstracts, Vol. 101, No. 17, issued 1984, October 22 (Columbus, Ohio, USA) C. Madhosingh et al. "Biodegradation of fatty acylamino acids by Fusarium culmorum", see page 236, column 2, the abstract no. 145 879g, J. Environ. Sci. Health, Part B 1984, B19(4-5), 491-9.	(1)

Anhang zum internationalen Recherchenbericht über die internationale Patentanmeldung Nr.

Annex to the International Search Report on International Patent Application No. PCT/HU 90/00004

Annexe au rapport de recherche internationale relatif à la demande de brevet international n°.

In diesem Anhang sind die Mitglieder der Patentfamilien der im obengenannten internationalen Recherchenbericht angeführten Patentedokumente angegeben. Diese Angaben dienen nur zur Unterrichtung und erfolgen ohne Gewähr.

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned International search report. The Austrian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche internationale visé ci-dessus. Les renseignements fournis sont donnés à titre indicatif et n'engagent pas la responsabilité de l'Office autrichien des brevets.

Im Recherchenbericht angeführtes Patentedokument
Patent document cited in search report
Document de brevet cité dans le rapport de recherche

Datum der Veröffentlichung
Publication date
Date de publication

Mitglied(er) der Patentfamilie
Patent family member(s)
Membre(s) de la famille de brevets

Datum der Veröffentlichung
Publication date
Date de publication

JP-A -63230663

JP-A2-63230663

27-09-88

JP-A -53052631

JP-A2-53052631

13-05-78

FR-A - 1603799

24-05-71

US-A - 3786076

15-01-74

US-A - 3904754

09-09-75

BE-A - 704363

01-02-68

DE-A - 1695498

16-03-72

DE-B2- 1695498

22-11-79

DE-C3- 1695498

31-07-80

GB-A - 1153408

29-05-69

JP-B4-51013121

26-04-76

NL-A - 6713780

16-04-68

FR-M - 6475

18-11-68

US-A - 3624114

30-11-71

None